Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ladarixin adjunctive therapy in overweight insulin-resistant adults with type 1 diabetes
2022-000743-68Phase 2Terminated
- Sponsor
- Dompé
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Ladarixin adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: HbA1c responder rate without severe hypoglycemia. Started May 2022; status: terminated.
02
Drugs
ladarixin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2022-000743-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000743-68.